INT201132

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.23
First Reported 2007
Last Reported 2007
Negated 0
Speculated 0
Reported most in Body
Documents 1
Total Number 11
Disease Relevance 1.77
Pain Relevance 0.11

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

plasma membrane (QRFPR) signal transducer activity (QRFPR)
Anatomy Link Frequency
capsule 2
Blood 1
urines 1
QRFPR (Homo sapiens)
Pain Link Frequency Relevance Heat
headache 77 78.68 Quite High
Bioavailability 22 63.76 Quite High
pruritus 22 38.52 Quite Low
abdominal pain 11 7.84 Low Low
Disease Link Frequency Relevance Heat
Arrhythmias 2 Under Development 44 97.96 Very High Very High Very High
Infection 33 92.24 High High
Malaria 198 83.92 Quite High
Diarrhoea 33 82.64 Quite High
Vomiting 55 82.08 Quite High
Dizziness 110 79.84 Quite High
Headache 77 78.68 Quite High
Disease 22 68.84 Quite High
Toxicity 77 65.32 Quite High
Respiratory Tract Infection 11 54.56 Quite High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Blood levels of AQ-13 and CQ peaked at similar times (Tmax 4.0 h [1.0–8.0 h] and 3.0 h [1.0–8.0 h] for AQ-13 and CQ), but had different maximal concentrations (Cmax 1.4 ?
Gene_expression (levels) of AQ-13 in Blood
1) Confidence 0.23 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.12 Pain Relevance 0
CQ produced greater prolongation of the QTc interval than AQ-13 (Table 6).
Gene_expression (produced) of AQ-13
2) Confidence 0.23 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
Despite prolongation of the QTc interval by both CQ and AQ-13, there were no cardiac AEs (Table 6).
Gene_expression (prolongation) of AQ-13
3) Confidence 0.20 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0
For the 1,500/1,750 mg therapeutic dose, volunteers received two 350 mg AQ-13 capsules or two 300 mg CQ capsules on days 1 and 2, and a single 350 mg AQ-13 or 300 mg CQ capsule on day 3 for doses of 1,750 mg AQ-13 (1,596.9 mg AQ-13 base) or 1,500 mg CQ.
Gene_expression (capsules) of AQ-13 in capsule
4) Confidence 0.20 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.16 Pain Relevance 0
After the 600 mg AQ-13 and CQ doses and the 700 mg (adjustment) AQ-13 dose, the QT interval was measured electronically from ECG recordings.
Gene_expression (dose) of AQ-13 associated with arrhythmias 2 under development
5) Confidence 0.20 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.10 Pain Relevance 0
Selection of AQ-13 as the Lead Compound
Gene_expression (Selection) of AQ-13
6) Confidence 0.20 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.47 Pain Relevance 0
In the comparison of the 1,500 mg therapeutic dose of CQ with 1,750 mg AQ-13, the 1,750 mg AQ-13 dose produced a smaller AUC?
Gene_expression (produced) of AQ-13
7) Confidence 0.20 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0 Pain Relevance 0.03
The data collected in this trial also showed that both AQ-13 and CQ were absorbed into the bloodstream in a similar way, but AQ-13 was absorbed more slowly than CQ.
Gene_expression (absorbed) of AQ-13
8) Confidence 0.20 Published 2007 Journal PLoS Clinical Trials Section Abstract Doc Link PMC1764434 Disease Relevance 0.59 Pain Relevance 0.08
For the 1,500/1,750 mg therapeutic dose, volunteers received two 350 mg AQ-13 capsules or two 300 mg CQ capsules on days 1 and 2, and a single 350 mg AQ-13 or 300 mg CQ capsule on day 3 for doses of 1,750 mg AQ-13 (1,596.9 mg AQ-13 base) or 1,500 mg CQ.
Gene_expression (capsules) of AQ-13 in capsule
9) Confidence 0.20 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.16 Pain Relevance 0
AQ-13 was produced as the dihydrochloride, trihydrate salt under Good Manufacturing Practice (GMP) conditions by Starks Associates (Buffalo, New York, United States) and CQ as the phosphate salt by Sanofi-Winthrop (New York, New York, United States).
Gene_expression (produced) of AQ-13
10) Confidence 0.18 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.12 Pain Relevance 0
Concentrations of AQ-13, CQ, and their metabolites were measured in whole blood and 24-hour urines with a fluorescence high-performance liquid chromatography (HPLC) assay using an Xterra RP18 analytical column with an elution buffer containing 60% borate (20 mM, pH 9.0) and 40% acetonitrile.
Gene_expression (Concentrations) of AQ-13 in urines
11) Confidence 0.18 Published 2007 Journal PLoS Clinical Trials Section Body Doc Link PMC1764434 Disease Relevance 0.05 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox